Coherus BioSciences
Stock Forecast, Prediction & Price Target
Coherus BioSciences (CHRS) stock Price Target by analysts
$6
Potential upside: 460.74%
Coherus BioSciences price prediction
What is Coherus BioSciences stock analysts` prediction?
Coherus BioSciences stock forecast: Based on 1 Wall Street analysts` predicted price targets for Coherus BioSciences in the last 3 months, the avarage price target is $6, with a high forecast of $NaN. The average price target represents a 460.74% change from the last price of $1.07.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Coherus BioSciences stock Price Target by analysts
Full breakdown of analysts given Coherus BioSciences price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Colleen Kusy Robert W. Baird | 0% 0/1 | 10 months ago | $6 460.74% upside | $1.74 | StreetInsider | Previous targets (0) |
Unknown J.P. Morgan | N/A | almost 3 years ago | $11 928.03% upside | $7.79 | Benzinga | N/A |
Ashwani Verma UBS | 100% 1/1 | over 3 years ago | $7 554.20% upside | $6.19 | TheFly | Previous targets (0) |
Coherus BioSciences Financial Estimates
Coherus BioSciences Revenue Estimates
Coherus BioSciences EBITDA Estimates
Coherus BioSciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $326.55M N/A | $211.04M -35.37% | $257.24M 21.89% | Avg: $353.51M Low: $322.99M High: $378.06M avg. 37.42% | Avg: $436.33M Low: $406.65M High: $460.60M avg. 23.42% | Avg: $500.23M Low: $466.21M High: $528.06M avg. 14.64% | Avg: $548.15M Low: $510.88M High: $578.65M avg. 9.57% |
Net Income
% change YoY
| $-306.32M N/A | $-326.62M -6.62% | $-237.89M 27.16% | Avg: $-14.87M Low: $-64.97M High: $29.07M avg. 93.74% | Avg: $37.40M Low: $7.53M High: $51.78M avg. 351.43% | Avg: $72.03M Low: $65.66M High: $77.24M avg. 92.59% | Avg: $79.09M Low: $72.10M High: $84.81M avg. 9.80% |
EBITDA
% change YoY
| $-264.14M N/A | $-253.05M 4.19% | $-193.93M 23.36% | Avg: $-134.72M Low: $-144.08M High: $-123.09M avg. 30.53% | Avg: $-166.28M Low: $-175.53M High: $-154.97M avg. -23.42% | Avg: $-190.64M Low: $-201.24M High: $-177.67M avg. -14.64% | Avg: $-208.90M Low: $-220.52M High: $-194.69M avg. -9.57% |
EPS
% change YoY
| -$4.06 N/A | -$4.21 -3.69% | -$2.53 39.90% | Avg: -$0.23 Low: -$0.69 High: $0.31 avg. 91.00% | Avg: $0.25 Low: $0.08 High: $0.55 avg. 209.73% | Avg: $0.77 Low: $0.7 High: $0.82 avg. 206.42% | Avg: $0.84 Low: $0.77 High: $0.9 avg. 9.80% |
Operating Expenses
% change YoY
| $532.81M N/A | $397.83M -25.33% | $301.45M -24.22% | Avg: $202.13M Low: $184.68M High: $216.16M avg. -32.94% | Avg: $249.48M Low: $232.51M High: $263.36M avg. 23.42% | Avg: $286.02M Low: $266.57M High: $301.93M avg. 14.64% | Avg: $313.42M Low: $292.11M High: $330.86M avg. 9.57% |
FAQ
What is Coherus BioSciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 136.89% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -64.97M, average is -14.87M and high is 29.07M.
What is Coherus BioSciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 21.26% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $322.99M, average is $353.51M and high is $378.06M.
What is Coherus BioSciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 129.24% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.69, average is -$0.23 and high is $0.30.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Coherus BioSciences stock. The most successful analyst is Colleen Kusy.